# US 12,180,463 B2 · Lactobacillus reuteri > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 12,180,463 B2 - Document ID: US12180463B2 - Status: Granted - Kind: B2 - Application number: 17/763,542 - Filed: 2020-09-24 - Published: 2023-05-11 - Granted: 2024-12-31 - Earliest claimed: 2019-09-26 - Assignees: PrecisionBiotics Group Limited - Applicants: Precisionbiotics Group Limited - Inventors: Jens Walter - Web page: https://patentgrep.com/patent/US12180463B2 ## CPC - C12N 1/205: Bacterial isolates - A23L 33/105: Plant extracts, their artificial duplicates or their derivatives - A23L 33/125: containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates (indigestible substances A23L33/21) - A23L 33/135: Bacteria or derivatives thereof, e.g. probiotics - A23L 33/40: {Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula} - A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis - A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs - A23V 2400/173: Reuteri - A61K 2035/115: {Probiotics} - C12R 2001/225: Lactobacillus - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION - C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS ## Abstract Lactobacillus reuteri strain having NCIMB accession number 42835 is from a novel phylogenetic clade and has unique immune-stimulatory properties and enhanced ecological performance in the human gut. A substrate for the strain, such as raffinose, may be administered at the same time as or separately from the strain. ## Claims ### Claim 1 A formulation comprising a strain of Lactobacillus reuteri deposited under NCIMB accession number 42835 mixed with an ingestible carrier, wherein the strain is in the form of a freeze-dried powder, and wherein the formulation is in the form of a capsule, a powder, a food product, or a beverage, the formulation being formulated for oral administration to a subject. ### Claim 2 (depends on 1) The formulation as claimed in claim 1, wherein the formulation further comprises a substrate, and the substrate is a carbohydrate. ### Claim 3 (depends on 1) The formulation as claimed in claim 1, wherein the formulation further comprises a substrate, and the substrate is an oligosaccharide. ### Claim 4 (depends on 1) The formulation as claimed in claim 1, wherein the formulation further comprises a substrate, and the substrate is derived from a plant source. ### Claim 5 (depends on 1) The formulation as claimed in claim 1, wherein the formulation further comprises a substrate, and the substrate comprises raffinose. ### Claim 6 (depends on 1) The formulation as claimed in claim 1, further comprising a prebiotic material. ### Claim 7 (depends on 1) The formulation as claimed in claim 1, wherein the formulation is in the form of a food product chosen from acidified milk, yoghurt, frozen yoghurt, milk powder, milk concentrate, ice cream, a cheese spread, a dressing; or wherein the formulation is in the form of a beverage. ### Claim 8 A method of treating a subject to increase gut microbiota diversity, the method comprising administering to the subject a formulation comprising Lactobacillus reuteri strain having NCIMB accession number 42835, wherein the strain is in the form of a freeze-dried powder, and wherein the formulation increases the gut microbiota diversity in the subject. ### Claim 9 (depends on 8) The method according to claim 8, wherein the subject is an infant, a young child, a pregnant female, or a mother post childbirth. ### Claim 10 (depends on 8) The method according to claim 8, wherein the formulation increases the growth of microbiota in the subject. ### Claim 11 (depends on 8) The method according to claim 8, wherein the formulation is in the form of a capsule, tablet, powder, food product, or beverage. ### Claim 12 (depends on 8) The method according to claim 8, further comprising administering a carbohydrate substrate to the subject. ### Claim 13 (depends on 12) The method according to claim 12, wherein the substrate comprises raffinose. ### Claim 14 (depends on 12) The method according to claim 12, wherein the substrate is administered at the same time as the formulation. ### Claim 15 (depends on 8) The method according to claim 8, wherein the subject has an inflammatory disorder. ### Claim 16 (depends on 1) The formulation according to claim 1, wherein the Lactobacillus reuteri strain is in the form of viable cells or non-viable cells. ### Claim 17 (depends on 3) The formulation according to claim 3, wherein the oligosaccharide is non-digestible. ### Claim 18 (depends on 1) The formulation as claimed in claim 1, wherein the strain is a probiotic material and the formulation further comprises a different probiotic material. ### Claim 19 (depends on 1) The formulation as claimed in claim 1, wherein the ingestible carrier comprises alcohol, silicone, a wax, petroleum jelly, a vegetable oil, polyethylene glycol, propylene glycol, a liposome, a sugar, gelatin, lactose, amylase, magnesium stearate, talc, a surfactant, silicic acid, viscous paraffin, perfume oil, a fatty acid monoglyceride, a fatty acid diglyceride, a petroethral fatty acid ester, hydroxymethyl-cellulose, or polyvinylpyrrolidone.